Tirzepatide is a peptide studied extensively for its activity across key metabolic and incretin pathways. It functions as a dual receptor agonist, acting on:
GLP-1 (glucagon-like peptide-1) receptors
GIP (glucose-dependent insulinotropic polypeptide) receptors
Through this dual mechanism, tirzepatide has been investigated for its effects on insulin secretion, regulation of hepatic glucose production, delayed gastric emptying, and appetite-related signalling.
This product is supplied as a pre-filled injectable pen intended for purchasers who have independently researched the compound and are operating under appropriate professional guidance.
Clinical Trial Evidence (Phase 3)
Tirzepatide has undergone extensive Phase 3 clinical evaluation in large, controlled trials.
In Phase 3 studies conducted under controlled conditions, tirzepatide demonstrated substantial and sustained reductions in body weight, with participants achieving average weight reductions of up to approximately 22–23% over 72 weeks, depending on dose and study protocol.
Phase 3 programmes also evaluated long-term safety, tolerability, and metabolic outcomes, forming the basis for subsequent regulatory approvals in certain jurisdictions.
Outcomes observed in clinical trials are dependent on controlled protocols and do not guarantee similar results outside of clinical settings.
How Tirzepatide Compares
Tirzepatide is often discussed alongside other incretin-based peptides:
Semaglutide functions as a GLP-1 receptor agonist only
Tirzepatide is a dual agonist, targeting both GLP-1 and GIP receptors
This dual activity differentiates tirzepatide from earlier single-pathway GLP-1 compounds
Important Information
Supplied as a pre-filled injectable pen
No dosing, administration, or medical instructions are provided
Consultation with a licensed healthcare provider is essential prior to any consideration of use
Results observed in clinical trials may not reflect real-world outcomes
This product is supplied strictly on an informed purchaser basis. By purchasing, you acknowledge that:
You have independently researched this product and its investigational status
You have consulted, or will consult, a qualified healthcare professional
The seller provides no medical advice, treatment claims, or dosing guidance
The onus of lawful, safe, and appropriate use rests entirely with the purchaser
